Effective December 19, 2024, the MLabs Chemistry Laboratory will begin offering four new drug screen panels to support the evolving and personalized needs for compliance and acute exposure testing. All the new panels will include a fentanyl screen by immunoassay and urine creatinine for specimen validity. Note that the urine creatine validity test is specific to the drug panels and not orderable individually. Testing will be performed on automated chemistry analyzers, Roche c503 to expedite TAT and support clinical decisions.
The current Drug Screen by Immunoassay panel (order code UDSIA) which includes screens for Amphetamines, Barbiturates, Benzodiazepines, Cannabinoids, Cocaine, Opiates and Oxycodone will remain available as an orderable option and will also include the Roche urine creatinine for specimen validity.
Components included in each panel are as follows:
|
UDSIA |
UDS8 |
UDS9B |
UDS9M |
UDS10 |
|
| Amphetamines |
X |
X |
X |
X |
X |
| Barbiturates |
X |
X |
X |
X |
X |
| Benzodiazepines |
X |
X |
X |
X |
X |
| Cannabinoids |
X |
X |
X |
X |
X |
| Cocaine |
X |
X |
X |
X |
X |
| Opiates |
X |
X |
X |
X |
X |
| Oxycodone |
X |
X |
X |
X |
X |
| Fentanyl |
|
X |
X |
X |
X |
| Buprenorphine |
|
|
X |
|
X |
| Methadone/EDDP |
|
|
|
X |
X |
| Urine Creatinine |
X |
X |
X |
X |
X |